Citation Impact
Citing Papers
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
2018 StandoutNobel
ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40–Mediated Tumor Rejection
2016 StandoutNobel
Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models
2015
The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
2014
Target-conditioned diffusion generates potent TNFR superfamily antagonists and agonists
2024 StandoutScienceNobel
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Co-incidence of RCC-susceptibility polymorphisms with HIF cis-acting sequences supports a pathway tuning model of cancer
2019 StandoutNobel
Controlling timing and location in vaccines
2020
Antibody Therapeutics in Cancer
2013 Science
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
2017
Necroptosis and its role in inflammation
2015 StandoutNature
Receptor Interacting Protein Kinase-3 Determines Cellular Necrotic Response to TNF-α
2009 Standout
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
2010
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Surviving apoptosis: life–death signaling in single cells
2015
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
The role of liposomes in clinical nanomedicine development. What now? Now what?
2019 Standout
Natural killer cell–directed therapies: moving from unexpected results to successful strategies
2008
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines
2023 StandoutNobel
Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study
2015
Trial Watch: Monoclonal antibodies in cancer therapy
2012
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
Functions of caspase 8: The identified and the mysterious
2014
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
2013
Cancer immunotherapy via dendritic cells
2012 Standout
CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs
2018
Hepatocellular carcinoma
2021 Standout
The immune contexture in cancer prognosis and treatment
2017 Standout
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
2016 StandoutNobel
Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer
2012
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
2021 StandoutNobel
Delivery technologies for cancer immunotherapy
2019 Standout
Cancer-associated cachexia
2018 Standout
Antibody therapy of cancer
2012 Standout
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
2015 Standout
Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo
2017
Targeting the apoptosis pathway in hematologic malignancies
2013
Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion
2013 StandoutNobel
Targeting apoptosis in cancer therapy
2020 Standout
Regulatory T cells in cancer immunotherapy
2016 StandoutNobel
Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
2014
Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy
2018 StandoutNobel
Biomaterials and emerging anticancer therapeutics: engineering the microenvironment
2015
Activation of apoptosis signalling pathways by reactive oxygen species
2016 Standout
Macrophages as regulators of tumour immunity and immunotherapy
2019 Standout
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Tumour-associated macrophages as treatment targets in oncology
2017 Standout
Combination cancer immunotherapies tailored to the tumour microenvironment
2015
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy
2009
Regulatory T cells in cancer immunotherapy
2014 StandoutNobel
A Tetravalent Sub-unit Dengue Vaccine Formulated with Ionizable Cationic Lipid Nanoparticle induces Significant Immune Responses in Rodents and Non-Human Primates
2016
Mitochondria as multifaceted regulators of cell death
2019 Standout
Clinical targeting of the TNF and TNFR superfamilies
2013
Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation
2013
The secret ally: immunostimulation by anticancer drugs
2012
Migrating into the Tumor: a Roadmap for T Cells
2017
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
2008
The TRAIL apoptotic pathway in cancer onset, progression and therapy
2008
Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity
2016
Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity
2014
Inflammasomes: mechanism of action, role in disease, and therapeutics
2015 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Cell death in health and disease
2007
Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons
2017 StandoutNobel
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
2019 StandoutNobel
E-Cadherin Couples Death Receptors to the Cytoskeleton to Regulate Apoptosis
2014
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
TRAIL-mediated signaling in prostate, bladder and renal cancer
2011
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer
2013
Inflammatory outcomes of apoptosis, necrosis and necroptosis
2014
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
Apoptosis: A Target for Anticancer Therapy
2018 Standout
Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases
2017 Standout
Regulatory T Cells and Human Disease
2020 StandoutNobel
Targeting Treg cells in cancer immunotherapy
2019 StandoutNobel
The TWEAK–Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice
2010
A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
2010
Pro-Inflammatory Cytokines TNF-Related Weak Inducer of Apoptosis (TWEAK) and TNFα Induce the Mitogen-Activated Protein Kinase (MAPK)-Dependent Expression of Sclerostin in Human Osteoblasts
2009
Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
2010
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
2013
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
2017 Standout
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
cFLIP Regulates Skin Homeostasis and Protects against TNF-Induced Keratinocyte Apoptosis
2013
Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions
2015
Influence of immunoglobulin isotype on therapeutic antibody function
2016
Acute dietary fat intake initiates alterations in energy metabolism and insulin resistance
2017
Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions
2015
Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook
2017
Adjuvant system AS01: helping to overcome the challenges of modern vaccines
2016
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
2014
Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment
2016
Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells
2014
Regulatory T cells expressing abundant CTLA‐4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer
2018 StandoutNobel
Innate or Adaptive Immunity? The Example of Natural Killer Cells
2011 StandoutScience
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
2018 StandoutNobel
Regulated Cell Death: Signaling and Mechanisms
2014
Works of Becky Yang being referenced
Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte–Associated Protein Blockade
2017
Activity of Apomab, a fully human agonistic DR5 monoclonal antibody, in models of non-Hodgkin’s lymphoma
2007
An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
2011
TRAF2 Sets a Threshold for Extrinsic Apoptosis by Tagging Caspase-8 with a Ubiquitin Shutoff Timer
2012
TWEAK Attenuates the Transition from Innate to Adaptive Immunity
2005
Proapoptotic Activation of Death Receptor 5 on Tumor Endothelial Cells Disrupts the Vasculature and Reduces Tumor Growth
2012
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts
2007
ISCOMATRIX vaccines mediate CD8+ T‐cell cross‐priming by a MyD88‐dependent signaling pathway
2011
Inflammasome-Dependent and -Independent IL-18 Production Mediates Immunity to the ISCOMATRIX Adjuvant
2014